SELUTION SLR 014 PTCA Drug-Eluting Balloon
MedAlliance, LLC · Decision date Sep 18, 2026
What did the FDA approve?
FDA records P250041 as an original PMA application. The recorded decision is approval, dated Sep 18, 2026.
FDA approval order statement
The SELUTION SLR 014 PTCA Drug-Eluting Balloon is intended to be used after appropriate vessel preparation in patients undergoing percutaneous coronary intervention (PCI) in coronary arteries 2.25 mm to 4.50 mm in diameter and lesions <= 26 mm in length for the purpose of improving myocardial perfusion when treating in-stent restenosis (ISR).
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 18, 2026
Regulatory record facts
- Identifier
- P250041
- Regulatory pathway
- Premarket approval application
- Applicant
- MedAlliance, LLC
- Product code
- OOB
- Decision code
- APPR
- Decision date
- Sep 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-eluting percutaneous transluminal coronary angioplasty catheter.
- Applicant
- MedAlliance, LLC
- Product code
- OOB
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250041 received
Application receipt date recorded by FDA.
P250041 · FDA decision
APPR
P250041/S001 · Related supplement
SELUTION SLR 014 PTCA Drug-Eluting Balloon
Timeline entries are records held by MedtechLedger for P250041. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250041
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SELUTION SLR 014 PTCA Drug-Eluting BalloonP250041/S001 | MedAlliance, LLC | PMA supplement | Nov 6, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
MedAlliance, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 4 Jenner, Suite 190, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P250041
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records